A new study identifies six genes active in both pancreatic cancer and metabolic diseases like obesity and type 2 diabetes, helping explain why patients with those conditions often face worse cancer outcomes. The findings could reshape how clinicians identify high-risk patients and develop targeted therapies.
Researchers at the University of Birmingham have uncovered a shared genetic and inflammatory thread connecting pancreatic cancer with obesity and type 2 diabetes — two conditions long known to raise the risk of developing the disease but whose biological ties to cancer have remained poorly understood. The study, published April 5 in the journal Cancer Medicine, identifies six specific genes that are consistently more active across all three conditions, offering a potential new framework for predicting cancer recurrence and designing more precise treatments.
A Deadly Cancer With Complex Risk Factors
Pancreatic ductal adenocarcinoma, or PDAC, is among the most lethal cancers. It is typically diagnosed at an advanced stage, responds poorly to existing therapies, and carries a recurrence rate of approximately 80% even in patients who undergo surgery. Despite this grim prognosis, relatively little is known about the molecular mechanisms that connect known risk factors — like obesity and diabetes — to cancer progression and relapse.
The new research set out to change that by testing whether genes already associated with PDAC recurrence also behave unusually in people with metabolic disease. Using a combination of large-scale human and mouse genetic datasets, single-cell analysis of pancreatic tumor tissue, and laboratory validation in human samples, the team found consistent evidence that the same biological machinery is at work in all three conditions.
“We know that people with obesity or diabetes tend to have worse outcomes from pancreatic cancer, but the biological reasons have not been clear. Our study shows that the same genes and inflammatory pathways are active in both metabolic disease and pancreatic cancer, which helps explain this link and points to new opportunities for identifying high‑risk patients and developing more targeted treatments,” senior author Animesh Acharjee, an associate professor of integrative analytics and AI at the University of Birmingham, said in a news release.
Six Genes at the Center
Across every stage of the analysis, the researchers found elevated activity in six genes: ITGAM, PECAM1, CCL5, STAT1, STAT2 and CD44. All six have previously been linked to pancreatic cancer recurrence. What makes this study notable is that each of these genes also showed heightened activity in the context of obesity and metabolic dysfunction — suggesting they may serve as a biological bridge between chronic metabolic disease and cancer biology.
These genes are known drivers of inflammatory and immune signaling pathways. Chronic low-grade inflammation is a hallmark of obesity and type 2 diabetes, and the findings suggest this persistent inflammatory environment may help set the stage for tumor growth and relapse in the pancreas.
Inside the Tumor: A Key Immune Cell Population
One of the study’s more granular findings emerged from single-cell analysis of pancreatic tumors. Within the tumor microenvironment — the complex ecosystem of immune, stromal and cancer cells surrounding a tumor — the researchers pinpointed a specific immune cell population where these six inflammatory pathways were especially active. This cell group appears to sit at the intersection of metabolic dysfunction and cancer progression, suggesting that the inflammation driven by obesity or diabetes may actively reshape the tumor microenvironment in ways that favor tumor survival and spread.
This kind of mechanistic insight is significant. It moves the conversation beyond epidemiological associations — the observation that obese or diabetic patients tend to do worse — toward an explanation of why that pattern exists at the cellular and molecular level.
How the Research Was Conducted
The team took an integrative, multi-stage approach to build their case. They began by mining publicly available genetic datasets from both humans and mice to compare gene expression in healthy individuals versus those with obesity. This cross-species analysis allowed them to identify patterns that were reproducible across biological systems.
Next, they layered in single-cell transcriptomic data from human pancreatic tumors to examine which cell types within the tumor were showing the most relevant inflammatory activity.
Finally, they validated their findings using actual human tissue samples in the laboratory, confirming that the candidate genes were indeed more active in obesity-associated contexts.
Why This Matters for Patients and Clinicians
The implications extend beyond basic science. If these six genes consistently flag both metabolic risk and cancer recurrence, they could eventually be incorporated into clinical tools that help identify which patients are most likely to relapse after surgery — allowing for earlier interventions or more aggressive monitoring. They might also serve as targets for new drug development, particularly therapies aimed at disrupting the inflammatory pathways that appear to fuel both metabolic disease and tumor progression.
“This study highlights how chronic inflammation and metabolic dysfunction can intersect with cancer biology. Understanding these shared mechanisms is essential if we are to improve outcomes for patients who are living with multiple long‑term conditions alongside cancer,” added co-author Simon Jones, a professor in musculoskeletal aging at the University of Birmingham and theme lead for the NIHR Biomedical Research Centre: Birmingham Sarcopenia and Multimorbidity research theme.
Funding and Next Steps
The study was funded by the Medical Research Council and Arthritis UK and was delivered through the National Institute for Health and Care Research (NIHR) Biomedical Research Centre: Birmingham.
For college students studying biology, public health, or medicine, findings like these underscore the growing importance of integrative, data-driven approaches in cancer research — and highlight how lifestyle-related conditions like obesity don’t just affect quality of life, but can fundamentally alter the biological landscape of a life-threatening disease.
Source: University of Birmingham